NCCN Guidelines Update: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic lymphocytic leukemia/small lymphoma (CLL/SLL) is characterized by the accumulation of abnormal lymphocytes in blood, bone marrow, and lymphoid tissues, leading to a weakened immune system an increased risk infections for patients. The NCCN Guidelines CLL/SLL underscore need comprehensive evaluation multiple factors determine most appropriate treatment approach each patient. For frontline therapy, selection process should consider patient’s IGHV status, del(17p)/ TP53 mutation age, comorbidities. In choosing subsequent prior comorbidities, resistance mutations be considered. With no clear evidence functional cure, it important enroll patients clinical trials when available.